Vmbook Online ordering
Cardium Therapeutics Inc
Cardium Therapeutics Inc. is a publicly-traded company listed on the OTCQB stock exchange under the ticker symbol "CXM". The company is a biotechnology company focused on developing and commercializing innovative therapies for diseases of the cardiovascular system. They specialize in developing regenerative medicine and gene therapy treatments for heart failure.
According to Yahoo Finance, Cardium Therapeutics Inc was founded in 2005, and is headquartered in San Diego, California. The company's mission is to develop innovative therapeutics that can help address unmet medical needs in cardiovascular diseases, with a focus on heart failure.
Cardium's lead product candidate is Generx, a registered trademark of Cardium Therapeutics, Inc. It is a rDNA-based angiogenic therapy designed to promote the growth of new blood vessels in the heart muscle. The company initiated a pivotal Phase 3 clinical trial evaluating the safety and efficacy of Generx in patients with severe coronary artery disease and chronic myocardial ischemia in 2020.
Cardium Therapeutics Inc. has a diverse pipeline of therapeutic candidates, including the acH48 illegal, chronic myocardial ischemia, and cardiac repair. Their product candidates are based on gene therapy and other innovative technologies to treat cardiovascular diseases.
Cardium's management team and scientists have extensive experience in developing and commercializing innovative therapies for cardiovascular disease. They have received funding from public and private sources, including the National Heart Lung and Blood Institute and the National Institutes of Health.
Cardium Therapeutics Inc. has a strong track record of partnering with leading organizations to advance their product candidates. They have collaborated with organizations such as the Mayo Clinic and the National Heart, Lung, and Blood Institute to conduct clinical trials.
Cardium Therapeutics Inc. is a small-cap company with a market capitalization of approximately 5.5 million USD, as of the last trade on the OTCQB stock exchange. Their stock price has been volatile over the past year, with a high of 0.023 USD and a low of 0.0067 USD. The company's 50-day moving average is currently 0.0132 USD.
Investors and potential investors should conduct thorough research and consult with a financial advisor before making any investment decisions. It is essential to analyze the company's financial statements, pipeline progress, and market trends before making any investment decisions. Investing in the stock market always carries risk, and there is no guarantee that the company's stock price will rise or that the company will succeed in bringing its products to market.
Investors can stay up-to-date with Cardium Therapeutics Inc.'s progress and development by visiting their website, https://cardiumthera.com/, or by following them on Facebook, Twitter, and LinkedIn.